Internal Medicine, Rheumatology · Gainesville, GA
NPI
1225122716
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
700 S Enota Dr NE
Gainesville, GA, 30501
Phone (770) 531-3711
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.7M
502,594 services
Medicare patients, 2024
685
Average age 74
Drug cost, 2024
$9.2M
6,446 prescriptions
Company payments, 2025
$2,712
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William A Chafin III was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 316,401 times for 99 patients. In total William A Chafin III billed 502,594 services in 78 codes, and Medicare paid $3.7M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-07-14.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 316,401 | 99 | $3.61 | $1.1M |
| J3262 Injection, tocilizumab, 1 mg | Office | 104,244 | 34 | $4.71 | $491K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 35,031 | 75 | $33.51 | $1.2M |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 19,740 | 35 | $9.03 | $178K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 5,320 | 83 | $0.10 | $543 |
| J9312 Injection, rituximab, 10 mg | Office | 4,100 | 21 | $61.19 | $251K |
| J0897 Injection, denosumab, 1 mg | Office | 1,381 | 18 | $20.68 | $29K |
| 96401 Chemotherapy Administration | Office | 1,375 | 116 | $52.72 | $72K |
| 99214 Office E&M - Established | Office | 1,305 | 505 | $88.56 | $116K |
| 96413 Chemotherapy Administration | Office | 834 | 178 | $94.40 | $79K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 825 | 19 | $0.23 | $190 |
| 36415 Venipuncture Blood Collection | Office | 821 | 376 | $8.62 | $7,077 |
| 85025 Blood Count | Office | 495 | 315 | $7.60 | $3,761 |
| 80053 Clinical Chemistry | Office | 492 | 314 | $10.33 | $5,084 |
| 86140 Clinical Chemistry | Office | 482 | 312 | $5.07 | $2,445 |
By year: 2022 $3.5M for 438,446 services; 2023 $3.4M for 444,090 services; 2024 $3.7M for 502,594 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 821 | 376 | $8.62 | $7,077 |
| 85025 Blood Count | 495 | 315 | $7.60 | $3,761 |
| 80053 Clinical Chemistry | 492 | 314 | $10.33 | $5,084 |
| 86140 Clinical Chemistry | 482 | 312 | $5.07 | $2,445 |
| 85652 Clinical Chemistry | 479 | 311 | $2.65 | $1,267 |
| 86235 Immunoassay | 105 | 15 | $17.57 | $1,845 |
| 83516 Immunoassay | 48 | 24 | $11.30 | $542 |
| 86480 Immunoassay | 33 | 33 | $60.74 | $2,004 |
| 86431 Immunoassay | 24 | 24 | $5.56 | $133 |
| 82306 Clinical Chemistry | 22 | 22 | $29.01 | $638 |
Medicare prescription drug claims, 2024
In 2024, the drug William A Chafin III prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,232 prescriptions and refills. In total William A Chafin III wrote 6,446 Medicare prescriptions that cost $9.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,232 | 3,205 | 380 | $61K |
| Methotrexate Methotrexate Sodium | 1,185 | 2,797 | 335 | $29K |
| Prednisone Generic | 939 | 1,439 | 462 | $4,269 |
| Enbrel Sureclick Etanercept | 354 | 390 | 43 | $2.9M |
| Humira(Cf) Pen Adalimumab | 185 | 190 | 31 | $1.3M |
| Orencia Clickject Abatacept | 174 | 181 | 18 | $1.0M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 162 | 162 | 44 | $2,576 |
| Celecoxib Generic | 137 | 277 | 44 | $4,141 |
| Leucovorin Calcium Generic | 132 | 285 | 41 | $1,954 |
| Gabapentin Generic | 113 | 252 | 36 | $1,686 |
| Colchicine Generic | 113 | 275 | 38 | $6,180 |
| Meloxicam Generic | 108 | 246 | 44 | $478 |
| Allopurinol Generic | 99 | 287 | 34 | $975 |
| Diclofenac Sodium Generic | 95 | 128 | 49 | $14K |
| Tramadol Hcl Generic | 89 | 89 | 39 | $346 |
Brand drugs: - claims; generic drugs: 5,258 claims; opioid claims: 274.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William A Chafin III $2,712 ($2,712 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $860.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 52 | $860 |
| Amgen Inc. AMGN | 18 | $351 |
| UCB, Inc. UCB.BR | 18 | $296 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $203 |
| Pfizer Inc. PFE | 6 | $132 |
| Janssen Biotech, Inc. JNJ | 6 | $123 |
| GlaxoSmithKline, LLC. GSK | 5 | $89.82 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $84.29 |
| Genzyme Corporation SNY | 3 | $79.96 |
| Octapharma USA, Inc. | 3 | $76.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.